Tumor Microenvironment and Immune Effects of Antineoplastic Therapy in Lymphoproliferative Syndromes

Table 1

Type of immune infiltration in Lymphomas and prognosis.

Type of lymphoma	Microenvironment	Prognosis
HL	↑↑ activated CTLs (Granzyme B^+)	Unfavourable
	↑↑ TIA-1^+ cells
	↓↓ FOXP3^+ cells
FL	Type 1 immune response pattern	Longer survival
	↑↑ T lymphocytes and regulatory T cells (FOXP3^+)	Favourable outcome
	Type 2 immune response pattern	Shorter survival
	↑↑ tumor-associated-macrophages (TAM, CD68^+) and NK cells (CD57^+)	Poor prognosis
DLBCL	↑↑ activated CD4^+ T cells, dendritic cells and macrophages	Better prognosis
	Infiltrate greater than 20% of CD4^+ cells, including CD45RO^+
	↑↑ FOXP3^+
	Higher expression of Th1 than Th2
	↓↓ IL-6 (Th2 response) during the first weeks after the therapy	Predict complete remission
	↓↓ TILs-CD8^+, ↑↑ activated CTLs	Poor prognosis
T and NK cell	↑↑ monocytes	Poor prognosis
	↓↓ FOXP3^+	Unfavorable
ALCL	↑↑ Granzyme B^+	Unfavorable
	↑↑ Granzyme B^+ and lack of expression of ALK	Poor prognosis